Key Takeaways TMO reported Q4 adjusted EPS of $6.57, up 7.7% year over year, while revenues rose 7.1% to $12.22B. TMO saw strength in Life Sciences and Laboratory Products offsetting slower growth in Analytical Instruments. TMO posted margin contraction as costs rose, even as cash and short-term investments jumped to $10.11B. Thermo Fisher Scientific Inc.'s (TMO) fourth-quarter 2025 adjusted earnings per share (EPS) of $6.57 beat the Zacks Consensus Estimate by 2.1%. The figure increased 7.7% year over year ...

Thermo Fisher Scientific (NYSE:TMO) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Company ParticipantsCasey Woodring - VP of Life Science Tools and Diagnostics Equity ResearchDan Arias - Managing Director of Life Science and DiagnosticsMarc Casper - Chairman, President and CEOMichael Ryskin - Managing Director in Healthcare Equity ResearchRafael Tejada - VP of Investor RelationsStephen Williamson - SVP and CFOConference Call ParticipantsDan Brennan - Life Science and Diagnostic Tools Research AnalystJa ...

Thermo Fisher Scientific (NYSE:TMO) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Company ParticipantsCasey Woodring - VP of Life Science Tools and Diagnostics Equity ResearchDan Arias - Managing Director of Life Science and DiagnosticsMarc Casper - Chairman, President and CEOMichael Ryskin - Managing Director in Healthcare Equity ResearchRafael Tejada - VP of Investor RelationsStephen Williamson - SVP and CFOConference Call ParticipantsDan Brennan - Life Science and Diagnostic Tools Research AnalystJa ...

Thermo Fisher Scientific (NYSE:TMO) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Speaker7Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 fourth quarter conference call. During the presentation, you can register a question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two on your telephone keypad. I would now like to introduce our moderator for the call, Mr. Rafael Tejada, Vice President, Investor R ...

Core Insights - Thermo Fisher Scientific Inc. (TMO) is set to release its fourth-quarter 2025 results on January 29, with earnings per share (EPS) expected to be $6.44, reflecting a 5.6% growth year-over-year [1][2][9] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for TMO's revenues is $11.95 billion, indicating a 4.9% increase from the same quarter last year [2][9] - TMO's earnings have consistently beaten estimates in the past four quarters, with an average surprise of 2.95% [1] Group 2: Segment Performance - The Analytical Instruments segment is anticipated to generate strong sales, particularly from electron microscopy and chromatography and mass spectrometry businesses [4] - The Life-Science Solutions segment is expected to report $2.89 billion in revenues, representing an 11.1% year-over-year improvement, driven by growth in the bioproduction business [10] - Specialty Diagnostics sales are projected to rise by 4.8% year-over-year, supported by new FDA approvals and product launches [9][13] Group 3: Recent Developments - TMO launched several new products, including the Orbitrap Exploris EFOX Mass Detector and new formulations for plasmid DNA production, which are expected to positively impact quarterly revenues [5][7] - The acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion is also anticipated to contribute favorably to TMO's performance [8] - TMO received FDA approvals for multiple diagnostic tests and launched new automated platforms, which are expected to enhance its top-line performance [11][12]